Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?

1.5.5 Semaglutide In a 52-week weight management trial ( n = 957 non-diabetic obese patients randomized to oral semaglutide 0.05–0.4 mg/day or placebo), hsCRP was reduced by up to 43% vs placebo in all semaglutide groups at week 52; these reductions were either significant or close to significance. 109 However, statistical significance was lost after adjustment for change in body weight. 109 In another 52-week randomized, open-label trial involving 412 T2DM patients on oral semaglutide 14 mg and 410 T2DM patients on empagliflozin 25 mg, greater decreases in CRP levels were observed at 52 wee

also in 2,130 other papers